跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PNPLA3
首页
药物
PNPLA3
PNPLA3
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
INHIBITION OF HSD17B13 IN THE TREATMENT OF LIVER DISEASE IN PATIENTS EXPRESSING THE PNPLA3 I148M VARIATION
EP 3695012 B1
申请人: REGENERON PHARMA
优先权: 2017
CN
EP
US
WO
12 件公开
MODULATORS OF PNPLA3 EXPRESSION
EP 3853365 A4
申请人: IONIS PHARMACEUTICALS INC
优先权: 2018
CN
EP
US
WO
10 件公开
EP 4045062 A1
申请人: ASTRAZENECA AB
优先权: 2019
CN
EP
US
WO
4 件公开
PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP 3256587 A2
申请人: ALNYLAM PHARMACEUTICALS INC
优先权: 2015
EP
US
WO
10 件公开
EP 4077666 A1
申请人: ALNYLAM PHARMACEUTICALS INC
优先权: 2019
CN
EP
US
WO
7 件公开
RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION
EP 3894555 A2
申请人: AMGEN INC
优先权: 2018
CN
EP
US
WO
7 件公开
RNAI AGENTS FOR INHIBITING EXPRESSION OF PNPLA3, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE
EP 4125932 A2
申请人: ARROWHEAD PHARMACEUTICALS INC
优先权: 2020
CN
EP
US
WO
7 件公开
NON-HUMAN ANIMALS COMPRISING A HUMANIZED PNPLA3 LOCUS AND METHODS OF USE
EP 4096396 A1
申请人: REGENERON PHARMA
优先权: 2020
CN
EP
US
WO
5 件公开
PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3 (PNPLA3) MODIFIERS
EP 4605076 A1
申请人: PFIZER
优先权: 2022
CN
EP
US
WO
4 件公开
Oligonucleotide compositions and methods of use thereof
US 11597927 B2
申请人: WAVE LIFE SCIENCES LTD
优先权: 2017
CN
US
4 件公开
COMPOSITIONS AND METHODS FOR MODULATING PNPLA3 EXPRESSION
EP 4323519 A1
申请人: DICERNA PHARMACEUTICALS INC
优先权: 2021
CN
EP
US
3 件公开
siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
US 10036024 B2
申请人: PURDUE RESEARCH FOUNDATION
优先权: 2017
US
3 件公开
第 1 / 4 页
上一页
下一页
药物
反馈